Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Regulator Strengthens Rules On Conflicts Of Interest For Expert Advisors

Executive Summary

The UK MHRA's code of practice has been updated in an effort to ensure that its decisions are based on “independent and impartial” expert advice and that the processes in place for managing conflicts of interest are “robust, consistent and clear to all.”

You may also be interested in...



UK Regulator To Overhaul Conflict Of Interest Rules

The number of committees and groups advising the MHRA has now topped 50, and the agency believes that now is the time for a wide-ranging reform of the way it identifies and manages conflicts of interest among the members of those bodies.

Coronavirus Notebook: UN Pandemic Declaration Disappoints, Focus Turns To Draft WHO Treaty

The World Health Organization has published a “step-by-step guide” for countries wishing to increase their capacity for monitoring pathogens with pandemic and epidemic potential. The EU and the UK have cleared an updated version of Moderna’s COVID-19 vaccine Spikevax targeting the XBB.1.5 variant, while the EU has followed the US in approving Gilead’s Veklury as the first treatment for COVID-19 patients with mild-to-severe liver damage.

EU Could Soon Have Three XBB.1.5 COVID-19 Vaccines For Winter Season

The head of the European Medicines Agency says a group of international regulators got together to ensure “global alignment” on the approach to be taken on COVID-19 vaccination. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel